OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE: NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.
“We’re thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for diagnosing the most difficult human diseases,” said Jon R. Cohen, MD, Executive Chairman of BioReference Laboratories. “With her depth of experience, focus on patient-centric business strategies and ability to lead and inspire, we look forward to a new era of genomics with GeneDx at the forefront.”
Ms. Stueland’s career is rooted in bringing transformational technologies to patients and crafting strategies to enable broader access to diagnostics and therapeutics. She has overseen multiple commercial organizations and corporate brand transformations, and helped bring the first cancer immunotherapy to market, enabling a new standard of care for patients.
“The global opportunity is clear regarding the growing role of genomic information in providing better care to patients. We can readily and rapidly provide critical information to improve health outcomes, and GeneDx has been at the forefront of these efforts for more than 20 years,” said Ms. Stueland, incoming President and CEO of GeneDx. “I’m honored to be joining this world-class team and couldn’t be more excited about what’s possible by bringing the GeneDx technologies to broader patient populations.”
With more than two decades in the healthcare industry, Ms. Stueland previously held roles at Dendreon Corporation and TAP Pharmaceuticals (a joint venture of Takeda and Abbott), and consulted for biotech and pharmaceutical companies.
GeneDx, Inc. is a global leader in genomics, providing testing to patients and their families from more than 55 countries. Led by its world-renowned clinical genomics program, GeneDx has an acknowledged expertise in rare and ultra-rare genetic disorders, as well as one of the broadest menus of sequencing services available among commercial laboratories. GeneDx offers a suite of additional genetic testing services, including diagnostic testing for hereditary cancers, cardiac, mitochondrial, neurological disorders, prenatal diagnostics and targeted variant testing. GeneDx is a subsidiary of BioReference Laboratories, Inc., a wholly owned subsidiary of OPKO Health, Inc. To learn more, please visit www.genedx.com.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected market reach, financial performance as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, financial condition, or strategies. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Released June 22, 2021